AR103172A1 - Reducción selectiva de residuos de cisteina en anticuerpos il-17 - Google Patents
Reducción selectiva de residuos de cisteina en anticuerpos il-17Info
- Publication number
- AR103172A1 AR103172A1 ARP150104191A ARP150104191A AR103172A1 AR 103172 A1 AR103172 A1 AR 103172A1 AR P150104191 A ARP150104191 A AR P150104191A AR P150104191 A ARP150104191 A AR P150104191A AR 103172 A1 AR103172 A1 AR 103172A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- antigen
- secukinumab
- preparation
- binding fragments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a métodos para reducir selectivamente CysL97 en una preparación de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos, ej., una preparación de anticuerpos de secukinumab, que ha sido producida de forma recombinante por células de mamífero, También se proporcionan preparaciones purificadas de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos producidos por tales métodos, por ejemplo, preparaciones purificadas de secukinumab, en donde el nivel de anticuerpos IL-17 intactos o fragmentos de unión a antígeno de los mismos (por ejemplo, secukinumab) en la preparación es alto, por ejemplo, al menos aproximadamente 90%, medido por electroforesis capilar de dodecil sulfato de sodio (CE-SDS), y en donde el nivel de actividad de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos (por ejemplo, secukinumab) en la preparación es alto, por ejemplo, al menos aproximadamente 92%, medido por cromatografía de intercambio catiónico (CEX).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095361P | 2014-12-22 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103172A1 true AR103172A1 (es) | 2017-04-19 |
Family
ID=55135470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104191A AR103172A1 (es) | 2014-12-22 | 2015-12-18 | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11292833B2 (es) |
| EP (2) | EP3237445A1 (es) |
| JP (4) | JP7021950B2 (es) |
| KR (3) | KR102873279B1 (es) |
| CN (4) | CN114249826B (es) |
| AR (1) | AR103172A1 (es) |
| AU (1) | AU2015370515B2 (es) |
| BR (1) | BR112017010069A2 (es) |
| CA (1) | CA2971541A1 (es) |
| IL (2) | IL298761A (es) |
| MX (1) | MX2017008410A (es) |
| PH (1) | PH12017500967A1 (es) |
| RU (2) | RU2719563C2 (es) |
| SG (1) | SG11201703639QA (es) |
| WO (1) | WO2016103146A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018085769A1 (en) * | 2016-11-07 | 2018-05-11 | Seattle Genetics, Inc. | Distribution of engineered-cysteine caps |
| DK3661562T3 (da) * | 2017-08-04 | 2024-12-16 | Amgen Inc | Fremgangsmåde til konjugation af cys-mabs |
| WO2020037016A1 (en) * | 2018-08-15 | 2020-02-20 | Bristol-Myers Squibb Company | Protein fragmentation control strategy by re-oxidation in downstream chromatography |
| CN109369806B (zh) * | 2019-01-14 | 2019-04-19 | 迈威(上海)生物科技有限公司 | 苏金单抗制品中半胱氨酸化变异体的去除方法 |
| JP7573261B2 (ja) * | 2020-07-28 | 2024-10-25 | 国立大学法人山梨大学 | 抗酸化剤及びその製造方法、医薬組成物及びその製造方法、食品、並びに化粧品 |
| EP4255927A1 (en) | 2020-12-02 | 2023-10-11 | Fresenius Kabi Deutschland GmbH | Methods of selectively reducing antibodies |
| JP2023554489A (ja) * | 2020-12-22 | 2023-12-27 | ノバルティス アーゲー | 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法 |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
| EP4406553A1 (en) * | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
| WO2024156841A1 (en) * | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
| CN118348098B (zh) * | 2024-03-31 | 2025-01-10 | 珠海联邦生物医药有限公司 | 一种用于毛细管电泳检测的凝胶分离缓冲液 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4766205A (en) | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| JP2669859B2 (ja) * | 1987-08-04 | 1997-10-29 | 協和醗酵工業株式会社 | タンパク質の再活性化法 |
| JP3610395B2 (ja) * | 1991-08-26 | 2005-01-12 | 敏一 中村 | 成熟肝実質細胞増殖因子 |
| ES2370235T3 (es) | 2001-02-23 | 2011-12-13 | Immunex Corporation | Recuperación eficaz de proteínas replegadas correctamente. |
| EP1452597A4 (en) | 2001-12-04 | 2006-09-20 | Mitsubishi Pharma Corp | PROCESS FOR ACTIVATING PROTEIN |
| DE60327715D1 (de) | 2002-12-20 | 2009-07-02 | Mitsubishi Tanabe Pharma Corp | Verfahren zum schutz von thiolgruppen in antikörpern |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2584211C (en) | 2004-10-22 | 2014-07-08 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| EP2360170A3 (en) | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| CN101374864A (zh) | 2006-01-31 | 2009-02-25 | 诺瓦提斯公司 | 用于靶向癌症的il-17拮抗性抗体 |
| WO2007092829A2 (en) | 2006-02-07 | 2007-08-16 | Shire Human Genetic Therapies, Inc. | Stabilized compositions of proteins having a free thiol moiety |
| PL4365189T3 (pl) | 2007-07-09 | 2025-05-26 | F. Hoffmann-La Roche Ag | Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów |
| CN102083460A (zh) | 2008-01-18 | 2011-06-01 | 米迪缪尼有限公司 | 用于位点特异性偶联的半胱氨酸工程化抗体 |
| BRPI1013016A2 (pt) | 2009-06-04 | 2016-03-29 | Massachusetts Inst Technology | "métodos para identificação de locais para conjugação de igg" |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| CN103154031A (zh) | 2010-10-08 | 2013-06-12 | 诺华有限公司 | 利用il-17拮抗剂治疗牛皮癣的方法 |
| HUE044038T2 (hu) * | 2010-11-05 | 2019-09-30 | Novartis Ag | Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával |
| AU2014259523B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating psoriatic arthritis using IL-17 antagonists |
| TW201307845A (zh) * | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 |
| JP5782279B2 (ja) | 2011-01-20 | 2015-09-24 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理方法および基板処理装置 |
| SI2771364T1 (sl) | 2011-10-27 | 2019-10-30 | Genmab As | Produkcija heterodimernih proteinov |
| AU2012341081B2 (en) | 2011-11-21 | 2015-06-04 | Novartis Ag | Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles |
| HRP20192076T1 (hr) * | 2013-02-08 | 2020-02-07 | Novartis Ag | Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja |
| MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
-
2015
- 2015-12-18 AR ARP150104191A patent/AR103172A1/es unknown
- 2015-12-21 CN CN202210002418.0A patent/CN114249826B/zh active Active
- 2015-12-21 WO PCT/IB2015/059824 patent/WO2016103146A1/en not_active Ceased
- 2015-12-21 SG SG11201703639QA patent/SG11201703639QA/en unknown
- 2015-12-21 CA CA2971541A patent/CA2971541A1/en active Pending
- 2015-12-21 CN CN201580066406.2A patent/CN107001460B/zh active Active
- 2015-12-21 AU AU2015370515A patent/AU2015370515B2/en active Active
- 2015-12-21 IL IL298761A patent/IL298761A/en unknown
- 2015-12-21 CN CN202111452382.8A patent/CN114010780B/zh active Active
- 2015-12-21 KR KR1020237038206A patent/KR102873279B1/ko active Active
- 2015-12-21 CN CN202210002380.7A patent/CN114316044A/zh active Pending
- 2015-12-21 RU RU2017126025A patent/RU2719563C2/ru active
- 2015-12-21 BR BR112017010069-0A patent/BR112017010069A2/en not_active Application Discontinuation
- 2015-12-21 JP JP2017551390A patent/JP7021950B2/ja active Active
- 2015-12-21 KR KR1020257034310A patent/KR20250154539A/ko active Pending
- 2015-12-21 RU RU2020113344A patent/RU2765307C2/ru active
- 2015-12-21 MX MX2017008410A patent/MX2017008410A/es unknown
- 2015-12-21 KR KR1020177016755A patent/KR102643328B1/ko active Active
- 2015-12-21 EP EP15823803.0A patent/EP3237445A1/en active Pending
- 2015-12-21 EP EP24170348.7A patent/EP4389143A3/en active Pending
- 2015-12-21 IL IL251893A patent/IL251893B2/en unknown
- 2015-12-21 US US15/538,266 patent/US11292833B2/en active Active
-
2017
- 2017-05-25 PH PH12017500967A patent/PH12017500967A1/en unknown
-
2022
- 2022-02-04 JP JP2022016666A patent/JP2022062194A/ja active Pending
- 2022-03-01 US US17/683,888 patent/US20220315650A1/en active Pending
-
2023
- 2023-06-01 JP JP2023091199A patent/JP2023110026A/ja not_active Withdrawn
-
2024
- 2024-08-12 US US18/800,977 patent/US20250034241A1/en active Pending
- 2024-10-16 JP JP2024181366A patent/JP2025011274A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103172A1 (es) | Reducción selectiva de residuos de cisteina en anticuerpos il-17 | |
| CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
| UY40829A (es) | Anticuerpos anti-phf-tau y sus usos | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| ECSP19005417A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| CL2019000259A1 (es) | Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584) | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| BR112015027812A2 (pt) | processo contínuo de multietapa para purificação de anticorpos | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| CL2018001414A1 (es) | Anticuerpos contra cd73 y sus usos (divisional solicitud 201701296) | |
| BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
| AR087715A1 (es) | Anticuerpos anti pcsk9 y usos de los mismos | |
| BR112017003236A2 (pt) | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica | |
| AR091218A1 (es) | Agente terapeutico o agente profilactico para los trastornos cognitivos | |
| AR096713A1 (es) | Proceso de purificación para anticuerpos monoclonales | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
| PE20211214A1 (es) | Variantes de pertuzumab y su evaluacion | |
| UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| CO6351750A2 (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5 | |
| EA201391523A1 (ru) | Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток | |
| MX2016009295A (es) | Cromatografia esteril y procesos de fabricacion. | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| MX386714B (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |